credit: NewLimit
The biotech startup, co-founded by the CEO of Coinbase, is working to restore “youthful function” in old cells via epigenetic reprogramming

For all the buzz surrounding longevity, we may be closer than ever to making good on the possibility of living longer, and it comes courtesy of the largest internal organ: the liver.

NewLimit, the San Francisco biotech startup co-founded by Coinbase CEO Brian Armstrong, just raised $435 million in a Series C round led by Peter Thiel’s Founders Fund, with plans to put its first age-reversing medicine into human trials next year.

A mix of new and returning investors participated in the round, including Valor Equity Partners (Neuralink and Eight Sleep) Eli Lilly Ventures and Human Capital.

The basic idea is that NewLimit’s medicines can restore “youthful function” in old cells via epigenetic reprogramming. In the case of the liver, the company says its therapy helps the football-sized organ heal faster after injury, resist damage from dietary challenges and recover quicker from alcohol consumption. 

Next year’s trial will reveal how the reprogramming translates into humans.

NewLimit has raised fast. The biotech closed a $40 million Series A in 2023, a $130 million Series B in May 2025 and a $45 million extension at a $1.6 billion valuation cap last fall.  But the science has moved even faster. NewLimit initially believed it would take more than a decade to bring such a product to trial.

“Over the coming years, we will add new therapeutic programs and bring a diverse portfolio of therapies into the clinic,“ NewLimit co-founder and president Jacob Kimmel wrote. “In the success case, we believe inventing medicines for aging is one of the few projects that can benefit humanity for centuries to come. As the world grows more abundant, health only becomes valuable.“

The new raise comes at an interesting time. Consumer demand for longevity is already there, with people paying for optimal health and longer lives through wearables, supplements, preventive diagnostics and longevity clinics, while “longevity bros,” like Bryan Johnson, launch their own healthspan startups. 

On the funding front, global investment in longevity companies hit $8.49 billion in 2024, more than double the prior year, spanning everything from drug development to smart rings, according to U.K.’s Longevity. Technology, a research, media and investment organization exclusively focused on the longevity industry.

UBS went further, calling longevity one of the most powerful investment themes of the next decade and projecting the business of living longer will hit $8 trillion by 2030.

Last month, Retro Biosciences, the Sam Altman-backed longevity startup focused on reversing age-related diseases, announced a financing round at a pre-money valuation of $1.8 billion.







Tags: